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ABSTRACT
In glioblastoma (GBM), infiltration of primary tumor cells into the normal tissue 
and dispersal throughout the brain is a central challenge to successful treatment that 
remains unmet. Indeed, patients respond poorly to the current therapies of tumor 
resection followed by chemotherapy with radiotherapy and have only a 16-month 
median survival. It is therefore imperative to develop novel therapies. RSK2 is a 
kinase that regulates proliferation and adhesion and can promote metastasis. We 
demonstrate that active RSK2 regulates GBM cell adhesion and is essential for cell 
motility and invasion of patient-derived GBM neurospheres. RSK2 control of adhesion 
and migration is mediated in part by its effects on integrin-Filamin A complexes. 
Importantly, inhibition of RSK2 by either RSK inhibitors or shRNA silencing impairs 
invasion and combining RSK2 inhibitors with temozolomide improves efficacy 
in vitro. In agreement with the in vitro data, using public datasets, we find that 
RSK2 is significantly upregulated in vivo in human GBM patient tumors, and that 
high RSK2 expression significantly correlates with advanced tumor stage and poor 
patient survival. Together, our data provide strong evidence that RSK inhibitors could 
enhance the effectiveness of existing GBM treatment, and support RSK2 targeting as 
a promising approach for novel GBM therapy.
INTRODUCTION
Glioblastoma (GBM) is an aggressive cancer that 
arises from glial cells and their progenitors and is often 
diagnosed at a late stage [1, 2]. GBM cells are highly 
motile and invade the healthy brain tissue surrounding 
the primary tumor site. This makes a complete surgical 
resection of GBM difficult, contributing to high recurrence 
and mortality rates in GBM patients [3, 4]. Furthermore, 
invading GBM cells are less sensitive to the current 
standard therapies including radiation and chemotherapy 
with DNA alkylating agents such as temozolomide [5, 
6]. GBM cells spread within the brain by migrating in 
a mesenchymal fashion along the extracellular matrix 
(ECM) of myelinated fiber tracts and blood vessels [7, 
8]. This migration is mediated by dynamic interactions 
between the cancer cell and its surrounding ECM through 
transmembrane signaling receptors including the integrins 
[9, 10].
The MAPK/ERK (Mitogen-activated protein kinase/
extracellular signal-regulated kinase) pathway reciprocally 
regulates integrin signaling [11, 12]. MAPK/ERK 
signaling controls integrin activity in part through the 
downstream target 90 kDa ribosomal S6 kinase 2 (RSK2) 
[13, 14]. RSKs are serine/threonine kinases that activate 
transcription and proliferation, and regulate apoptosis 
[15–17]. RSK inhibitors have revealed additional roles for 
RSKs in controlling proliferation of prostate and breast 
cancer cells [18–20] and differentiation of muscle cells 
[21]. Recent work has shown that RSKs are required 
for invasion and metastasis of many cancers [22–24]. 
All RSK isoforms contain two kinase domains, a central 
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regulatory linker domain, and a carboxyl-terminal ERK 
docking site [16, 25, 26]. The N-terminal kinase domain 
(NTKD) is in the AGC kinase family and appears to be 
responsible for phosphorylation of all substrates. The 
C-terminal kinase domain (CTKD) is in the CaM kinase 
family and regulates the NTKD. Activation of RSKs 
requires phosphorylation at multiple sites. Initially 
ERK phosphorylates the CTKD at Thr573 and a linker 
site at Ser369. The CTKD then phosphorylates Ser380 
and thereby generates a docking site for PDK1. PDK1 
binds and phosphorylates Ser221 in the NTKD [27, 28]. 
Phosphorylation at Tyr529 by either FGF receptor 3 (in 
myeloid cells) or Src and Fyn (in fibroblasts) can enhance 
inactive ERK binding to RSK2 [29, 30]. RSK2 directly 
phosphorylates filamin A (FLNa). FLNa is a large protein 
that forms an elongated homodimer that crosslinks F-actin 
and affects invasion [31–33]. Activation of RSK2 by ERK 
promotes FLNa phosphorylation and enhances its binding 
to integrin complexes thereby modulating focal adhesion 
composition and activity [34]. FLNa binds to the integrin 
cytoplasmic tail at an NPxY sequence that also interacts 
with talin [35]. As a result, FLNa and talin may compete 
for integrin-binding [35]. Finally, FLNa association with 
the integrin cytoplasmic tails maintains the integrin in the 
inactive state [36].
GBMs harbor alterations in receptor tyrosine 
kinases such as MET and epidermal growth factor receptor 
(EGFR) and proteins downstream in the Ras-MAP kinase 
and the PI3 kinase-AKT-mTOR pathways [37]. Other 
important pathways in GBM are Wnt, sonic hedgehog, 
Rb, and p53 [38]. We here focus on the activation of the 
Ras-MAP kinase pathway, which in its turn activates 
RSKs. Deregulation of the Ras-ERK MAP kinase pathway 
contributes significantly to the development, progression, 
and invasiveness of GBM. An activating mutation in 
EGFR resulting from deletion of the extracellular variant 
III region occurs in 20-30% of all primary GBMs, while 
amplification of EGFR is seen in 40-70% of primary 
GBMs [37, 38]. In addition mutations or amplifications 
have also been identified in MET, and downstream 
of EGFR in Ras [39], B-Raf [39, 40] and RSK2 [41]. 
Finally, therapeutics that block invasion can also increase 
chemotherapeutic sensitivity of GBM [42].
RSK2 acts as mediator of cell migration and 
invasion, thereby driving tumor aggressiveness. Since 
GBM is characterized by a high degree of invasiveness, 
we hypothesized that RSK2 signaling is involved in the 
progression of this malignancy. In this study, we report 
that RSK enzymatic activity is an important regulator 
of GBM invasiveness in vitro. RSK co-localizes with 
FLNa at the plasma membrane and modulates GBM 
cellular adhesion. We find that targeting RSK’s enzymatic 
activity results in reduced in vitro GBM cell motility 
and invasion. Moreover, combining perturbation of RSK 
function with standard chemotherapy temozolomide 
enhanced temozolomide’s effectiveness in patient GBM 
cells resistant to temozolomide. In addition, we show 
that RSK2 is upregulated in human GBM patient cells, 
correlates with tumor grade, and is a significant predictor 
of poor patient survival. Our findings support targeting 
RSK enzymatic activity as a potential novel therapeutic 
approach for GBM.
RESULTS
RSK2 activity is required for GBM cell 
migration and invasion
We previously found that RSK2 kinase activity is 
the driving force behind its regulation of cellular motility 
[14]. Thus, we predicted that RSK2 activity is required 
for GBM cell migration. We therefore tested the effects 
of RSK inhibition on in vitro migration of an established 
GBM-derived cell line (U-373 MG). Treatment with the 
RSK inhibitors FMK and BI-D1870 impaired transwell 
cell migration along a fibronectin/EGF gradient in these 
cells (Figure 1A). All four RSK isoforms appear to be 
expressed in all GBM cell lines tested at levels higher than 
in the control astrocytes (Figure 1B). Loss of RSK activity 
also inhibited GBM cell invasion, as RSK inhibitor 
treatment of U-373 MG cells resulted in impaired three-
dimensional outgrowth (Figure 1C, D).
The RSK inhibitor BI-D1870 inhibits all four 
RSK isoforms while FMK inhibits RSK1, -2, and -4. We 
therefore determined if RSK2 specifically was required 
for invasion using shRNA silencing in U373 cells. We 
found that U373 cells were dependent on RSK2 for 
invasion (Figure 2A), Cell viability was not affected in 
these treatments (Figure 2B) and the level of knockdown 
of each RSK isoform is shown (Figure 2C). These findings 
confirm the requirement of RSK2 kinase activity for GBM 
tumor invasion.
RSK2 co-localizes with FLNa and modulates 
GBM cellular adhesion
Integrin-based cell adhesion is a crucial regulator of 
mesenchymal cancer cell migration [43]. We previously 
reported that RSK2 controls cell motility in HeLa and 
neuroblastoma cells in part by changing integrin activation 
status and hence adhesion due to FLNa phosphorylation 
and subsequent FLNa association with integrin tails [14, 
44]. We therefore examined whether RSK2 co-localizes 
with FLNa in migrating U373MG cells. EGF stimulation 
increased the density of cortical actin in membrane ruffles. 
We found that in addition to nuclear translocation, we saw 
an association of RSK2 and FLNa at the cell membrane 
(Figure 3). Since RSK2 co-localizes with FLNa in 
migrating cells, it could influence migration through direct 
phosphorylation of FLNa as previously described [34].
We hypothesized that RSK2 also controls integrin 
activity in GBM cells, resulting in changes in cellular 
adhesion and migration. We therefore determined if 
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RSK activity had direct impact on GBM adhesion. We 
found that cells treated with the RSK inhibitor BI-D1870 
were significantly more adherent to 3FN-(9–11), the 
recombinant cell-binding domain of fibronectin (Figure 
4A). Loss of RSK2 activity affected cell adhesion as early 
as 10 min after plating the cells. Conversely, transient 
transfection of a dominant active mutant of RSK2 (RSK-
Y707A) impaired cell attachment, resulting in reduced 
overall adhesion at multiple time-points (Figure 4B).
GBM invasion in the brain requires association 
of the GBM cells with a complex microenvironment 
that is not fully replicated using 2D and 3D matrices. 
Furthermore, the current RSK inhibitors are quickly 
degraded in vivo and are therefore not suitable for 
testing in situ in mouse xenograft models. We therefore 
examined the effect of RSK inhibition with BI-D1870 or 
RSK knock-out using CRISPR/Cas9 deletion on U373 
GBM cell invasion into mouse brain slices. These slices 
are 200 μm thick and are cultured in media to maintain 
an environment more relevant to in vivo invading GBM 
tumor cells. In both tests we found significantly reduced 
invasion when RSK activity is reduced (Figure 4C, 4D). 
Figure 1: RSK isoforms are required for GBM migration and invasion. A. Migration of U-373 cells was determined in the 
presence of RSK inhibitors (FMK and BID1870) or control DMSO. Relative migration into the scratch was measured at 24 hours. B. 
Immunoblot showing expression of RSK1-4 isoforms in the indicated cells. C. Day 4 U-373MG tumor spheroids were embedded in 
either 100% matrigel or D. a 50% Matrigel/50% collagen mixture (right panel) and treated with DMSO or 10 μM BI-D1870. Images were 
acquired at 0, 24, and 48 hours after addition of drug. Bar graphs show the quantification of the normalized area of the spheroids as the mean 
of 3 independent experiments (carried out in duplicates, n = 6).
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Figure 2: Individual RSK isoforms regulate GBM cell invasion in 3D. A. Stable U-373 MG cell lines with knocked down 
RSK1, -2, -3, or -4 isoform expression (shRSK1-4) or cells carrying a scrambled control vector (scr) were generated using two independent 
shRNA constructs targeting RSK1-4. RSK1-4 knock-down and control cell lines were subjected to a tumor spheroid invasion assay. 
Spheroids were embedded in a 50% matrigel-50% collagen I matrix and invasion was analyzed after 48 hours. Quantification at 48 hours 
is shown. B. RSK1-4 isoform knock-down had no effect on GBM cell viability at 48 hours. C. Protein knock-down levels were determined 
by immunoblotting as indicated.
Figure 3: RSK2 co-localizes with FLNa. U-373 MG cells were grown on coverslips coated with 10 μg/ml fibronectin. Cells were 
serum starved overnight and then stimulated for 5 or 30 min with 10 ng/ml EGF. Cells were fixed and stained for RSK2 and FLNa using 
specific primary antibodies. Immunostaining was visualized with confocal microscopy using a 63x objective. Scale bars shown represent 
30 μm (5 μm in the zoom pictures).
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Together these results support the conclusion that RSK2 
activity is a potent regulator of integrin-dependent cell 
adhesion and GBM cell migration and invasion.
RSK2 activity drives patient-derived GBM cell 
migration and invasion
Since GBM-derived cell lines, whether cultured on 
plastic or on brain slices, are not perfect representatives of 
primary GBM cells, we examined if RSKs were similarly 
required for migration and invasion of fresh GBM patient-
derived cells. We found that RSKs are expressed in GBM 
cells from many different patients (Figure 5A, B). Activity 
of RSKs, as indirectly measured using phospho-epitope 
antibodies to pS386 and pT573, also was elevated in some 
patient cells (Figure 5A). We concluded that increased 
RSK2 levels may contribute to GBM progression and 
promote tumor recurrence. We therefore tested the effects 
of RSK2 gene knockout or chemical inhibition on the 
migratory capabilities of the patient-derived primary GBM 
cell line SK748. This cell line was uniquely maintained 
as suspended tumor neurospheres, an in vitro culture 
technique in which cell lines better retain characteristics 
consistent with fresh patient cells [45, 46]. Scratch 
migration assays with SK748 showed that both RSK2 
knock-out and chemical inhibition (with BI-D1870) 
decreased cell migration (Figure 5C). Similarly, RSK2 
gene knock-down with shRNA and chemical inhibition 
significantly blocked GBM SK748 invasion in transwell 
assays with epidermal growth factor (EGF) and fibroblast 
growth factor (FGF) as chemoattractants (Figure 5D). 
Neither RSK2 gene knock-down nor chemical inhibition 
affected cell viability, proliferation, or morphology in 
these assays, as confirmed through microscopic analysis 
(Figure 5E). RSK2 kinase activity is therefore required for 
primary patient-derived GBM migration.
Figure 4: RSK2 activity reduces cell adhesion to fibronectin and invasion into brain slices. We examined early adhesion of 
U-87 MG cells on culture plates coated with 3FN-(9–11). Before plating, cells were A. pre-treated with 10 μM BI-D1870 or DMSO carrier 
control or B. transiently transfected with DA-RSK2 or a pcDNA3 empty vector control. 48 hours after transfection or 15 min after pre-
treatment cell adhesion was measured. Bar graphs show the number of cells adherent after the indicated amount of time. The experiment 
was carried out in 3 independent repeats. Error bars shown as SEM. Statistically significant differences are marked with asterisks (* P < 
0.05, ** P < 0.01, *** P < 0.001). Scale bar: 500 μm. C and D. We examined the ability of U373 cells treated with BI-D1870 inhibitor (C) or 
with RSK2 knocked out using CRISPR/Cas9 (D). Whole brain slices of 300 μm thickness were placed on the membrane of a six-well plate 
culture insert. GBM cell lines U373MG, U373MG with RSK2 gene knock-down (KO-RSK2), or U373MG with a non-targeting shRNA 
(NT-RSK2) were labeled with the PKH67 fluorescent linker. After 7 days, one small spheroid of approximately 200 μm was transferred to 
each brain slice as close to the corpus callosum as possible. The co-cultures were maintained for an additional 72 hours. To quantify the 
invasiveness of the spheroids, the density of the fluorescent signal was measured in each 20 μm section using ImageJ Software. Shown are 
the migration depths. Error bars are shown as SEM.
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RSK inhibition enhances the effectiveness of 
standard GBM therapy
GBM invasion targeting has been shown to 
enhance the effectiveness of the current standard 
therapies temozolomide and irradiation [3]. We 
therefore tested whether RSK2 function interference 
would enhance the effectiveness of temozolomide and 
irradiation therapy using GBM neurospheres derived 
from a patient with temozolomide resistance (GBM8) 
in vitro. We found that GBM8 cells were resistant to 
temozolomide and irradiation, with cell viabilities > 50% 
at 100 μM drug or 4 Gy irradiation treatment. Combined 
treatments did not increase cell death. Interestingly, 
RSK2 gene knock-down sensitized the patient cells to 
temozolomide, especially at higher concentrations (10 
μM and 100 μM; Figure 6A). RSK2 gene knock-down 
also improved the anti-tumor effect of BI-D1870 as the 
Figure 5: Patient-derived GBM cells require RSK2 for invasion and migration. A. RSK1-4 are expressed in patient cells 
and are phosphorylated at S386 and T573 indicating likely activation. B. Quantification of RSKs normalized to tubulin with cumulative 
expression in patients indicated for each. C. Quantification of scratch assay migration experiments and D. transwell assay. At 24 hours, 
RSK2 gene knock-down cells and wild-type cells treated with BI-D1870 significantly decreased cell migration in both scratch (t-test; P = 
0.0036 and 0.00043, respectively) and transwell assays (t-test; P = 0.0061 and 0.011, respectively). Images of example scratch assays are 
shown (C). Scratch assays were quantified using ImageJ and normalized to time 0 h. E. There was no effect on cell number or morphology 
in the migration assays.
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cell viability dramatically decreased while we noted 
little change in control cells containing non-targeting 
control shRNA (Figure 6B). This is probably due to the 
sub-optimal effects of RSK2 shRNA function and/or 
compensation by additional RSK isoforms. Importantly, 
although low concentrations of either temozolomide or 
BI-D1870 alone had little effect on cell proliferation, 
combinations showed an additive anti-tumor effect (1 
μM temozolomide with 1 μM BI-D1870; Figure 6C, 
6D). Therefore, the combination of RSK inhibition with 
temozolomide is a promising new therapeutic approach 
in GBM treatment.
RSK2 expression is elevated in human glioma 
tissue, correlates with high tumor grade, and is 
prognostic for poor patient outcome
In this study, we performed in vitro experiments 
on both GBM cell lines and fresh GBM patient-derived 
cells, that all showed a role for RSK2 in GBM migration/
invasion and therapy resistance. To verify that our results 
also apply in vivo, in human patients, we performed 
RSK2 mRNA expression analyses in large human glioma 
datasets in the public domain. We note that RSK2 mRNA 
studies can provide only surrogate markers for RSK2 
Figure 6: Inhibition of RSK2 sensitizes resistant patient-derived GBM to temozolomide. We investigated the effect of RSK2 
in combination with temozolomide treatment and irradiation on GBM patient cells that were resistant to chemotherapy and radiation. A. 
RSK2 gene knock-down sensitized GBM cells to temozolomide and the RSK1-4 inhibitor BI-D1870. At high temozolomide concentrations, 
the cell viability decreased from 57% to 8% (P < 0.001). In addition, 10 μm RSK inhibitor BI-D1870 decreased cell viability from 58% 
to 9% (P < 0.001). RSK2 gene knock-down had no significant effect on radiation response. B. RSK Inhibitor BI-D1870 enhanced the 
anti-tumor effect of temozolomide in RSK2 gene knock-down cells. For resistant wild-type cells, temozolomide/BI-D1870 combination 
treatment (both at 1 μM), decreased cell viability to 51% as compared to single reagent treatment effects of 91% and 72% remaining 
viability (P < 0.001 and P < 0.01, respectively). C and D. The combination of temozolomide and BI-D1870 was more effective at killing 
GBM cells than either alone.
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enzymatic activity, but in the absence of large public 
datasets on enzymatic activity in cancer this is the best 
information available. First, by comparison of the brain 
samples in the large “Human Body Map” with the three 
largest, best annotated public glioma datasets, we observed 
that RSK2 mRNA expression is significantly lower in 
normal brain tissue than in human glioma samples (Figure 
7), in concordance with a tumor-promoting role for RSK2 
in glioma. Brain tissue is very heterogeneous, and RSK2 
expression could vary considerably between the different 
brain tissue subtypes. However, we find that the variances 
in RSK2 expression in normal brain tissue and in the 
three human glioma tissue datasets are relatively small 
and comparable in size, suggesting that RSK2 expression 
variations also occur in glioma. Further support for higher 
expression of RSK2 in tumor tissue compared to normal 
tissue is obtained from comparing glioma tumor stages. 
We found that RSK2 tumor mRNA expression is higher in 
aggressive, metastatic, grade 4 tumors than in lower grade 
(2 and 3) tumors in three distinct patient cohorts (Figure 
8). This also suggests that RSK2 expression in tumors is 
correlated to in vivo metastasis. Finally, using Kaplan-
Meier analysis, we were able to determine that the survival 
of glioma patients with low tumor RSK2 expression is 
significantly higher than that of glioma patients that have 
high RSK2 expression in their tumors. This result was 
found for the three largest patient cohorts in the public 
domain (Figure 9), suggesting this correlation is robust. 
We conclude that in vivo high RSK2 expression is linked 
to metastasis and poor survival in complete agreement 
with our in vitro studies.
DISCUSSION
Malignant gliomas are among the most aggressive 
and deadly forms of cancer and can affect any age group 
[3]. In high-stage glioma, GBM, infiltration of primary 
tumor cells into normal tissue and dissemination throughout 
the brain is a central but unmet challenge to successful 
treatment [38]. Indeed, patients with GBM respond poorly 
to the standard therapeutic regimen of radiotherapy and 
chemotherapy that follow tumor resection. The median 
survival is about 16 months [38]. It is therefore imperative 
to identify novel approaches to specifically attack GBM 
cell survival, proliferation and invasion. We have found 
that RSK2 can drive GBM migration and invasion. This 
appears to be mediated in part through RSK2 effects on 
FLNa and subsequent changes in integrin activity and 
Figure 7: RSK2 mRNA expression is higher in human glioma than in normal brain tissue. Differential RSK2 mRNA 
expression between the largest collection of normal human brain tissue (from the Roth-504 “Human Body Map”), and the three public 
human glioma datasets used in further analyses. RSK2 expression is significantly lower in normal brain than in glioma tissue, although 
glioma mRNA expression can vary between datasets. Y-axis presents RSK2 mRNA expression, X-axis dataset (in bracket the number of 
samples in the analysis). For presentation reasons, only GBM (stage 4) samples were used, but the differences remain significant when all 
dataset samples are analyzed (results not shown). Bars represent average ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
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cell adhesion. Inhibition of RSK isoforms in combination 
with temozolomide increased temozolomide effectiveness 
in vitro. As a first indication of the applicability of our in 
vitro results in new clinical routes, we find that RSK2 is up-
regulated in human glioma cells, correlates with high-stage, 
metastatic disease, and is a significant predictor for poor 
patient survival. RSK inhibitors may therefore serve as new 
combination therapeutics.
Figure 8: RSK2 mRNA expression correlates with high human glioma tumor stage. Correlation of RSK2 tumor mRNA 
expression with WHO glioma tumor grade (grades 2-4) was analyzed using the Kruskal-Wallis test. Shown are graphs representing the 
three largest public glioma datasets with full WHO grade annotation: A. French-284, B. Kawaguchi-50, C. Sun-153). Y-axis presents RSK2 
tumor mRNA expression (rank-based), X-axis WHO-grade. In all three datasets, RSK2 expression is significantly higher in stage 4 than in 
stage 2 or 3 tumors. Bars represent average ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001.
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We previously showed that RSK2 modulates cell 
adhesion and integrin activity and thereby regulates cell 
motility [14]. It does so in part by phosphorylating its 
target FLNa, a negative regulator of integrin activation 
[36, 47], and promoting FLNa association with the 
integrin cytoplasmic tails. We now find that RSK2 alters 
adhesion and migration in GBM cells. We find that RSK 
co-localizes with FLNa and that active RSK disturbs 
the initial adhesion of GBM cells to ECM. This likely 
contributes to the increased motility in these cells. RSK 
can also effect a migration program through transcription 
as well as changes in the actin cytoskeleton. We now find 
that these functions of RSK are active in GBM and that 
RSK inhibition limits GBM invasion.
RSK inhibitors generally affect all RSK isoforms 
(RSK1-4). However, not all RSKs control cell motility 
in the same way. While RSK2 often promotes migration 
of cancer cells [23], RSK1 has been shown to negatively 
regulate cell motility [48]. The observed effects in GBM 
cells might therefore be due to a broad inhibition of all 
RSK isoforms and their cellular functions. Thus, we tested 
the effect of individual RSK isoform gene knock-down 
in the GBM U373MG cell line and found that RSK2 can 
regulate invasion in these cells and in the temozolomide 
resistant primary patient-derived GBM cells. Additionally, 
the BI-D1870 inhibitor seems to block invasion more 
potently than gene knock-down of any specific RSK 
isoform. This may be due to a requirement for the 
activation of multiple RSK isoforms, redundancy in RSK 
isoform function, incomplete shRNA activity, or off-
target effects of the inhibitor. Thus, additional studies are 
necessary to determine how each individual RSK isoform 
Figure 9: RSK2 mRNA expression is prognostic for poor glioma patient prognosis. Prognostic significance of RSK2 tumor 
mRNA expression in human glioma patients as determined by Kaplan-Meier analysis. Shown are Kaplan-Meier graphs representing the 
overall survival prognosis of glioma patients based on high or low RSK2 tumor mRNA expression in the three largest public glioma 
datasets with survival data: A. French-284, B. TCGA-540 (both screenshots from the R2 website), and C. REMBRANDT-523 (screenshot 
from the Betastasis website). It should be noted that the color indications for patients with high or low tumor RSK2 expression is different 
for panels (A)/(B) versus (C). No conflicting results were found in other public glioma datasets. The graphs present patient groups separated 
at median RSK2 tumor mRNA expression. Y-axis presents survival probability, X-axis months of follow up. In all three datasets, high 
RSK2 expression is prognostic for poor outcome. This prognostic significance was also found for average RSK2 expression cut-off.
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influences invasion and whether some of these isoforms 
have redundant functions in cell migration and invasion.
Further testing of RSK2 gene knock-down and 
the BI-D1870 inhibitor confirmed the ability to block 
migration in patient-derived GBM cell lines. Additionally, 
Kaplan-Meier analysis showed that high tumor RSK2 
expression was prognostic for poor outcome, suggesting 
that RSK2 inhibitors like BI-D1870 may provide an 
interesting lead in targeting invasion in GBM treatment. 
The current standard of treatment is temozolomide 
combined with radiotherapy. We therefore tested whether 
combining RSK inhibition with temozolomide and 
radiotherapy had an additive effect. We found that RSK 
inhibition alone could reduce primary patient-derived 
GBM neurosphere survival and the combination of 
temozolomide with RSK inhibition was significantly 
more effective than either treatment alone. No additional 
effect of radiotherapy was noted for these cells. We note 
that our in vitro data and bio-informatics clinical data 
cannot substitute in vivo drug experiments, and that 
final confirmation of our findings awaits these studies. 
Currently there are no RSK inhibitors suitable for in vivo 
studies because their in vivo degradation kinetics are too 
unfavorable. Therefore, there is a pressing need to identify 
additional inhibitors that can maintain activity in animal 
models to do pre-clinical testing of RSK inhibitors.
Taken together, our study describes a novel function 
for RSK2 in the regulation of GBM cell motility and 
invasion. Therefore, inhibition of RSK2, and thereby 
metastasis reduction in GBM, is a promising new approach 
for addition to current standard therapies.
MATERIALS AND METHODS
Cell lines and reagents
Human astrocytes were purchased from ScienCell 
Research Laboratories (catalogue #1800, Carlsbad CA) 
and cultured according to manufacturer’s instructions. 
Human glioblastoma (GBM) cell line U-87 MG was 
obtained from the NCI-Tumor Repository (Frederick, 
MD). U-373 MG was a gift from Dr. Santosh Kesari 
(UCSD School of Medicine, La Jolla, CA). Cells were 
cultured in D-MEM (U-87 MG, U-373 MG) or RPMI (SF-
295; ATCC) (Mediatech, Manassas, VA). Basal media were 
supplemented with 10 % fetal bovine serum (HyClone, 
VWR, Radnor, PA), 1% non-essential amino acids and 1% 
penicillin/streptomycin (Cellgro, Manassas, VA). Cells 
were incubated in a humidified atmosphere containing 
5% CO2 at 37 °C. Transient transfections with the 
indicated constructs were performed using Lipofectamine 
(Life Technologies, Carlsbad, CA) according to the 
manufacturer’s protocol. Antibodies specific for RSK2 
(C-19), α-tubulin (DM1A); phospho p90RSK (Ser386) 
were from Life Technologies, antisera for RSK1 
(#9333S), and RSK3 (#9343S) were from Cell Signaling; 
antiserum for RSK4 was from Abgent (AP7944a), and 
for FLNa (SAB4500951) from Sigma-Aldrich (St. Louis, 
MO). The RSK specific inhibitor SL0101 was purchased 
from Tocris Bioscience (Ellisville, MO), FMK was a gift 
from J. Taunton (University of California, San Francisco, 
CA) and BI-D1870 was obtained from BioVision Inc. 
(Milpitas, CA). Temozolomide (Temodar, S1237) was 
obtained from Selleckchem (Houston, TX).
Isolation and culture of GBM primary cells 
derived from patients
Fresh human GBM material was acquired from 
GBM surgical patients and cultured as previously 
reported [45, 46]. Institutional Review Boards of the 
UC San Diego Human Research Protections Program 
reviewed and approved this project in accordance with the 
requirements of the Code of Federal Regulations on the 
Protection of Human Subjects. The IRB granted a waiver 
of informed consent for the recruitment component of this 
project. All analysis on human material and data was in 
compliance with the “Declaration of Helsinki for Medical 
Research involving Human Subjects” (www.wma.net/
en/30publications/10policies/b3/index.html). Briefly, 
the dissociated tissue was washed, filtered through a 
30 μm mesh and plated onto ultra-low adherence flasks 
at a concentration of 500,000 to 1,500,000 viable cells/
ml. The stem cell isolation medium included human 
recombinant EGF (20 ng/ml), human bFGF (10 ng/ml) 
and heparin (2 μg/ml). Sphere cultures were then passaged 
by dissociation, washed, re-suspended in neural stem 
cell culture medium (#05750, Stemcell Technologies, 
Vancouver, Canada), and plated on ultra low-adherence 
96-well plates at 2,000 cells per well for all subsequent 
drug testing. Alternatively, patient-derived dissociated 
GBM tissues were plated onto laminin-1 coated plates 
(Sigma, 3-5 μg/ml). Cell populations were dissociated 
using Acutase (Sigma) and expanded for 5-10 passages, 
then plated on regular flat bottom culture flasks.
Lentiviral gene knock-down
U-373 MG cell lines with stable RSK isoform gene 
knock-down were generated using lentiviral particles 
containing shRNA expression constructs and subsequent 
selection with 4 μg/ml puromycin dihydrochloride (Santa 
Cruz Biotech). Lentiviral particles with pools of targeting 
sequences against RSK1 (sc-29475-V), RSK2 (sc-
36441-V), RSK3 (sc-36443-V), RSK4 (sc-39212-V), or 
scrambled control shRNA lentiviral particles (sc-108080) 
were obtained from Santa Cruz Biotechnology and used 
according to the manufacturer’s protocol. Lentiviral 
particles containing either pGIPZ non-silencing control or 
one of four shRNAs constructs targeting RSK2 (Thermo 
Scientific, Waltham, MA) were produced as previously 
described [49], and U-87 MG cells were transduced as 
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previously described [50]. SK748 primary cells were 
transduced and selected with puromycin 1 μg/ml for 
1 week.
Transwell migration assay
The bottom side of cell culture inserts (8 μm 
pore size; Corning, Lowell, MA) was coated with 10 
μg/ml human plasma fibronectin (Life Technologies). 
Cells were plated in the insert top chambers in serum 
free media, with the bottom chambers containing 
incomplete media supplemented with 10 ng/ml EGF. 
Cells were incubated for 18-20 hours at 37°C. The 
number of cells that migrated through the membrane 
was measured through Calcein-AM dye (Sigma-Aldrich) 
uptake and fluorescence at 495 nm excitation/515 nm 
emission. Transwell assays with primary GBM patient 
cells were performed by plating 10,000 cells in the top 
chambers of transwell inserts suspended in neural stem 
cell media supplemented with either DMSO or 5 μM BI-
D1870, while the bottom chamber contained complete 
media supplemented with EGF and FGF. Cells were 
incubated for 24 hours at 37°C. The top chamber was 
fixed, stained with crystal violent and cell number was 
counted on both sides using an inverted microscope 
(Olympus).
Cell migration scratch assay
Patient-derived GBM cells with RSK2 gene or 
control knock-down (shRSK2 or –NT) were grown 
in 6-well culture plates in neural stem cell media 
supplemented with either DMSO or 5 μM BI-D1870. 
The knockdown lentiviral vector expresses GFP to 
monitor transduced cells. The cells were allowed to 
grow to confluence then scratched with a 200 μL pipette 
tip. The cells were then washed in serum free media and 
replaced with media containing 1% serum. Cells were 
allowed to migrate into the scratch for various time 
points. Images of the scratch were acquired immediately 
after scratching (t=0) and at 24 hours. The average 
closure of the scratch by GFP-expressing migrating cells 
was measured using ImageJ software, and expressed as 
relative migration normalized to the t0 distance.
Cell viability assay
Patient derived GBM8 cells with RSK2 gene or 
control knock-down (shRSK2 or –NT) were seeded on 24-
well plates then irradiated at 0, 2 and 4 Gy the following 
day. After radiation, temozolomide was added to final 
concentrations of 1, 10, or 100 μM, and BI-D1870 to 1 or 
10 μM. Cell viability was measured by Alarm Blue assay 
after 7 days of treatment. We also tested the combination 
of 1 μM temozolomide and 1 μM BI-D1870 on GBM8 
control knock-down (ShNT) cells.
Tumor spheroid invasion assay
Tumor spheroids were produced using U-87 MG 
cells as previously described [51] and embedded in 
100% matrigel or a 50% matrigel/50% collagen mixture 
supplemented with either DMSO or 10 μM BI-D1870. 
Images were acquired 0, 24, and 48 hours after addition 
of the drug using an inverted microscope. The relative 
area of each spheroid was normalized (ImageJ) by 
dividing the area of a spheroid at 24 or 48 hours by its 
area at 0 hours.
Adhesion assay
To measure cell adhesion, U-87 MG cells were 
harvested with a non-enzymatic cell dissociation buffer 
(Cellstripper, Cellgro, Mediatech) and plated in 96-
well glass bottom plates coated with 10 μg/ml 3FN-
(9–11) fusion protein. After the indicated amount of 
time pictures were taken using an IX81 microscope 
(Olympus) and an objective with 10x magnification. To 
quantify adhesion, the adherent cells in the pictures were 
counted.
Immunofluorescence
Cells were grown on glass coverslips coated with 
10 μg/ml fibronectin. At about 50 % confluency, cells 
were fixed in 2 % paraformaldehyde, permeabilized 
in 0.1 % Triton X-100 in PBS, and blocked with 1 
% goat serum. Cells were incubated with primary 
antibodies for 1 hour. Alexa Fluor 488, 594 and 647 
secondary antibodies (Life Technologies) were used to 
fluorescently label bound primary antibody. Coverslips 
were mounted on slides using Fluoromount G (Electron 
Microscopy Sciences, Hatfield, PA). Images were 
acquired on a Leica TCS-SP5 confocal microscope using 
a 62x oil-immersion objective (Leica Microsystems, 
Wetzlar, Germany).
Immunoblotting
Cells were lysed with MLB lysis buffer (Millipore, 
Billerica, MA) as previously described [44]. Cell 
lysate protein was resolved by sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). 
Expression and phosphorylation of proteins was 
determined by immunoblotting using specific primary 
antibodies. Binding of primary antibodies was detected 
using IRDye 680 goat anti-mouse and IRDye 800 goat 
anti-rabbit secondary antibodies (Li-Cor Biosciences, 
Lincoln, NE). Bands were visualized using an Odyssey 
Infrared Imaging System (Li-Cor Biosciences). Scanned 
blots were cropped to improve clarity and conciseness of 
presentation using Adobe Photoshop CS (Adobe Systems 
Inc., San Jose, CA).
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Brain slice invasion assay
Mus musculus brain slices were cultured as 
previously described [52]. Whole brain slices of 300 
μm thickness were placed on the membrane of six-well 
plate culture insert (PICM 030 5, Millipore) and washed 
once with PBS supplemented with magnesium (1 mM) 
and calcium (1 mM). The brain slices were cultured in 1 
ml Eagle’s MEM (111, Corning, Corning, NY), 25 mM 
HEPES, 25% HBSS, 25 % heat-inactivated horse serum, 
6.5 mg/ml D-glucose, 100 U/ml penicillin, 100 μg/ml 
streptomycin, and 2.5 μg/ml amphotericin B). Thereafter, 
half of the medium was refreshed every three days. After 
the second change, the amount of culture medium was 
reduced to 800 μl. GBM cell lines (U373MG, U373MG 
(KO-RSK2), U373MG (NT-RSK2)) were labeled with 
the PKH67 fluorescent linker (MINI67, Sigma-Aldrich) 
according to the manufacturer’s instructions. The tumor 
spheroids were formed by seeding 1 x 107 labeled cells 
into a 60 mm ultra-low attachment dish (3261, Corning) 
containing 5 ml of D-MEM (10-013-CV, Corning) 
containing 10% FBS, 1X MEM nonessential amino 
acids (25025CL, Corning), 100 U/ml penicillin, 100 μg/
ml streptomycin) and grown for several days. The day 
before implantation of the tumor spheroids, brain slices for 
inhibitor experiments were treated with 10 μM of RSK2 
inhibitor BI-D1870 or vehicle. After 7 days, the viability of 
the brain slice was verified by the presence of the cortical 
lamination and hippocampal structure; then the insert was 
transferred to a well of a glass-bottom 6-well plate (P06G-
1.5-20-F.S, MatTek, Ashland, MA). One small spheroid 
of approximately 200 μm was transferred to each brain 
slice as close to the corpus callosum as possible. The 
co-cultures were maintained for an additional 72 hours. 
The tumor cell invasion was followed using a confocal 
microscope (TCS SP5, Leica) and a stage-top incubator 
with digital gas mixer (TokaiHit WSKM/GM8000, 
Fujinomiya-shi Shizuoka-ken, Japan). The basal plane (0 
μm) was determined 4 hours post implantation and serial 
sections every 20 μm downward from the basal plane to 
the bottom of the slice were imaged at the indicated time 
points. Propidium iodine staining of the brain slices at the 
end of the assay confirmed that the brain slice cultures 
had remained viable. To quantify the invasiveness of 
the spheroids, the density of the fluorescent signal was 
measured in each 20 μm section using ImageJ Software 
(National Institutes of Health, Bethesda, MD).
Public human glioma mRNA expression 
dataset analysis
Human glioma mRNA expression datasets in the 
public domain were analyzed using R2: a genomics 
analysis and visualization platform developed in the 
Department of Oncogenomics at the Academic Medical 
Center – University of Amsterdam (http://r2.amc.nl). 
The human adult glioma datasets analyzed for this study; 
French-284 (GSE16011, [53]), Kawaguchi (GSE43378, 
unpublished), Sun-153 (GSE4290, [54]), and TCGA-540 
(TARGET, [55]) were the only public datasets with WHO 
grade annotation and/or survival data. Human normal brain 
tissue samples were retrieved from the Roth-504 dataset 
(GSE7307, unpublished). Expression data (CEL files) 
were downloaded from the Gene Expression Omnibus 
(GEO) [56] on the NCBI website (http://www.ncbi.
nlm.nih.gov/geo/) or from TARGET (https://ocg.cancer.
gov/programs/target). Data were analyzed as described 
in [57]. Briefly, gene transcript levels were determined 
from data image files using GeneChip operating software 
(MAS5.0 and GCOS1.0, Affymetrix, Santa Clara, CA). 
Samples were scaled by setting the average intensity of 
the middle 96 % of all probe-set signals to a fixed value of 
100 for every sample in the dataset, allowing comparisons 
between micro-arrays. The TranscriptView genomic 
analysis and visualization tool within R2 was used to 
check if probe-sets uniquely mapped to an anti-sense 
position in an exon of the gene (http://r2.amc.nl > genome 
browser). The probe-sets selected for RSK2 (203843_at 
for Affymetrix U133A and –P2, and 226335_at for 
Affymetrix U133P2) meet these criteria. For each dataset, 
the results obtained with the probe-set with the highest 
average expression in the highest amount of samples are 
shown, but the other probe-set never showed conflicting 
results. In addition, the independent Betastasis genomics 
analysis and visualization platform was queried for the 
REMBRANDT-523 human adult glioma Affymetrix 
U133P2 dataset (http://betastasis.com/glioma), using 
website standard settings. All expression values and other 
details for the datasets used can be obtained thru their 
identifiers from the NCBI GEO, TARGET, or Betastasis 
websites. Differential RSK2 mRNA expression between 
normal human brain and glioma tissue (Figure 7) was 
determined using a two-sided Student’s t-test. RSK2 
mRNA expression correlation with glioma WHO grade 
(Figure 8) was determined using the non-parametric 
Kruskal-Wallis test. The correlation between RSK2 tumor 
mRNA expression and survival probability (Figure 9) was 
evaluated by Kaplan-Meier analysis using the log-rank test 
as described [58]. For all tests, P < 0.05 was considered 
statistically significant.
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